Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$36.95 USD

36.95
1,964,098

+0.37 (1.01%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $36.96 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Globus Medical Sees Strong Rebound Despite Coronavirus Crisis

by Zacks Equity Research

Globus Medical (GMED) witnesses a significant rebound from mid-April through the remainder of Q2.

Zacks Equity Research

Medtronic Publishes IN.PACT AV Access Trial Study Results

by Zacks Equity Research

Medtronic's (MDT) IN.PACT AV demonstrates significant reductions in hospital visits for AV fistulae maintenance, which is leading to successful and uninterrupted dialysis of ESRD patients.

Nalak Das headshot

7 Top-Ranked Corporate Giants With More Than 50% Return YTD

by Nalak Das

A handful of corporate giants (market capital > $10 billion) have skyrocketed this year, braving the pandemic and its impact on businesses.

Zacks Equity Research

QIAGEN Launches Primer Panel for NGS of Coronavirus Genome

by Zacks Equity Research

QIAGEN (QGEN) expands the NGS portfolio with the launch of the genome analyzing panel to support holistic research of the SARS-CoV-2.

Zacks Equity Research

Omnicell (OMCL) Hurt by Coronavirus-Led Lower Product Booking

by Zacks Equity Research

Omnicell (OMCL) is currently witnessing slowdown in purchasing decisions by hospitals.

Zacks Equity Research

Has QIAGEN N.V. (QGEN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (QGEN) Outperforming Other Medical Stocks This Year?

Urmimala Biswas headshot

Will Thermo Fisher's (TMO) Failed QIAGEN Deal Cost it a Lot?

by Urmimala Biswas

The COVID-19 tailwinds are significantly stronger than what Thermo Fisher (TMO) had originally expected in March.

Zacks Equity Research

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors continue to be upbeat about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.

Zacks Equity Research

Boston Scientific's Voraxaze's MAA Accepted by EMA for Review

by Zacks Equity Research

Boston Scientific's (BSX) business arm's MMA for Voraxaze (glucarpidase) accepted by EMA for review.

Zacks Equity Research

Amedisys Banks on Coronavirus-Driven Growth Amid Cost Woes

by Zacks Equity Research

Amedisys (AMED) has been benefiting from the recent acquisitions of hospice care providers.